PART I Item 1. B usiness Overview We are a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through discovery and development of novel live biotherapeutic product, or LBP, candidates. We led the successful development and approval of VOWST, the first FDA-approved orally administered microbiome biotherapeutic and a Breakthrough Therapy designated drug, which was sold to Socit des Produits Nestl S.A., or SPN, and with certain of its affiliates, colle...
Q2 FY2026 — expected 2026-08-18
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-12 | 2025-12-31 | 0001193125-26-103276 | EDGAR | 108K words |
| 2025-03-13 | 2024-12-31 | 0000950170-25-038427 | EDGAR | — |
| 2024-03-05 | 2023-12-31 | 0000950170-24-025464 | EDGAR | — |
| 2023-03-07 | 2022-12-31 | 0000950170-23-006374 | EDGAR | — |
| 2022-03-01 | 2021-12-31 | 0000950170-22-002435 | EDGAR | — |
| 2021-03-02 | 2020-12-31 | 0001564590-21-010057 | EDGAR | — |
| 2020-03-02 | 2019-12-31 | 0001564590-20-008002 | EDGAR | — |
| 2019-03-06 | 2018-12-31 | 0001564590-19-006423 | EDGAR | — |
| 2018-03-08 | 2017-12-31 | 0001564590-18-004830 | EDGAR | — |
| 2017-03-16 | 2016-12-31 | 0001564590-17-004551 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-05 | 2025-09-30 | 0001193125-25-266011 | EDGAR | 67K words |
| 2025-08-06 | 2025-06-30 | 0000950170-25-103611 | EDGAR | — |
| 2025-05-07 | 2025-03-31 | 0000950170-25-065173 | EDGAR | — |
| 2024-11-13 | 2024-09-30 | 0000950170-24-126018 | EDGAR | — |
| 2024-08-13 | 2024-06-30 | 0000950170-24-095821 | EDGAR | — |
| 2024-05-08 | 2024-03-31 | 0000950170-24-055159 | EDGAR | — |
| 2023-11-02 | 2023-09-30 | 0000950170-23-057805 | EDGAR | — |
| 2023-08-08 | 2023-06-30 | 0000950170-23-039439 | EDGAR | — |
| 2023-05-09 | 2023-03-31 | 0000950170-23-019222 | EDGAR | — |
| 2022-11-02 | 2022-09-30 | 0000950170-22-021018 | EDGAR | — |
| 2022-08-03 | 2022-06-30 | 0000950170-22-014052 | EDGAR | — |
| 2022-05-04 | 2022-03-31 | 0000950170-22-007217 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-16 | 0001193125-26-108482 | EDGAR | 1K words |
| 2026-03-12 | 0001193125-26-103034 | EDGAR | — |
| 2026-03-02 | 0001193125-26-085368 | EDGAR | — |
| 2025-11-05 | 0001193125-25-265708 | EDGAR | — |
| 2025-10-03 | 0001193125-25-230118 | EDGAR | — |
| 2025-08-06 | 0001193125-25-173985 | EDGAR | — |
| 2025-07-22 | 0001193125-25-162552 | EDGAR | — |
| 2025-05-07 | 0001193125-25-114430 | EDGAR | — |
| 2025-04-22 | 0001193125-25-089189 | EDGAR | — |
| 2025-04-14 | 0001193125-25-080185 | EDGAR | — |
182 total filings indexed. 150 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001609809 |
| Ticker | MCRB |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.serestherapeutics.com |
| Listed | 2015-06-26 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report